On November 20, 2017, oncologist Thomas Bauernhofer at the University Hospital Graz and colleagues from the Institutes for Biophysics and Pathology at the same university in Austria made a discovery that may save thousands of women’s lives. The extraordinary find was reported in Oncotarget.
The researchers were seeking a better understanding of why 30 percent of women who are diagnosed with breast cancer die despite early detection and treatment. The scientists examined biopsy samples from women who were suspected of having breast cancer and found a new biomarker that distinguishes the women who are most likely to die from breast cancer. The biomarker is the GIRK1 protein.
The researcher found two methods of detecting the GIRK1 protein. The discovery introduces the potential for a genetically modified treatment that hinders the protein from expressing itself in breast cancer. There are other systems that are associated with the GIRK1 protein. Those systems may be simpler and easier targets to produce higher survival rates in the 30 percent of women who die due to this protein.
Oncotarget announced that it will publish internationally twice weekly on September 19, 2017. . Oncotarget is a free open access publication that has been publishing on line since 2010. The main concentration of the publication is oncology. The volumes include peer reviewed articles about discoveries in chromosomes, pathology, immunology, aging, microbiology, and autophagy.
Oncotarget has followed the strict structure of the majority of scientific literature. These priorities include a direct object identifier for each paper and the application of COPE standards to all publications. The original idea behind Oncotarget is unique. The publication aims to distribute the latest scientific information as rapidly as possible. Free access allows the less well funded researchers the same opportunity to learn and improve their practice and the health of their patients.
Oncotarget achieved one of its goals by submitting an entire issue to PubMed post online release. The National Library of Medicine assisted Oncotarget in this achievement. Oncotarget is and will be available on EMBASE, PubMed Central, BIOSIS Previews, ISI/Web of Science: Science Citation Index, Biological Abstracts, and Scopus. Oncotarget has the unique ability to publish research from any country in the world. The publication has even featured new advanced methods from countries that usually are not seen in major mainstream publications.